MINI FUTURE LONG - AMGEN | Real-time Bid/Ask 05:15:48 20/05/2024 pm IST | ||
| 20.07 EUR / 20.2 EUR | +0.52% |
|
| Current month | +18.80% | ||
| 1 month | +25.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 20.08 | +0.25% |
| 17/24/17 | 20.03 | -1.14% |
| 16/24/16 | 20.26 | -1.79% |
| 15/24/15 | 20.63 | +3.41% |
| 14/24/14 | 19.95 | +1.32% |
Delayed Quote Börse Stuttgart
Last update May 20, 2024 at 01:12 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MA7AKE |
| ISIN | DE000MA7AKE9 |
| Date issued | 07/06/2021 |
| Strike | 94.42 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 11.75 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.61 € |
|---|---|
| Lowest since issue | 9.33 € |
| Spread | 0.11 € |
| Spread % | 0.55% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.5
USD
Average target price
314.6
USD
Spread / Average Target
+0.70%
- Stock Market
- Certificates
- Certificat
